HomeEXECUTIVESMark Turco, MD Appointed President of Xenter’s Medical Technologies Business Unit

Mark Turco, MD Appointed President of Xenter’s Medical Technologies Business Unit

Mark Turco, MD, has been appointed President of Xenter Medical Technologies (formerly Xenter Hospital Technologies). Xenter’s Medical Technologies business unit is developing a new global platform of smart medical devices, initially focusing on vascular imaging and physiology technologies for interventional medical procedures.

Mark Turco, MD joins Xenter most recently from Sirtex Medical where he served as Executive Vice President of Research and Development and Global Chief Medical Officer, leading the development and delivery of interventional oncology technologies worldwide. Prior to Sirtex, Dr. Turco served as Chief Innovation and Corporate Outreach Officer for the University of Pennsylvania’s Penn Center for Innovation, where he led Penn’s corporate outreach team, fostered multiple industry and academic partnerships across healthcare, engineering, and business, and established a new medical device center.

Mark Turco, MD began his 20-year clinical practice at Washington Adventist Hospital in Washington, DC, where he served as the Director, Center for Cardiac and Vascular Research before joining Covidien as Chief Medical Officer. Following Medtronic’s $47B acquisition of Covidien in 2015, Dr. Turco was appointed Vice President and Chief Medical Officer of the Aortic, Peripheral & Vascular Divisions at Medtronic prior to joining Penn.

“I am very excited to join Xenter in this pivotal leadership role,” said Dr. Turco. “I look forward to aiding in the development of medical technologies using Xenter’s three pillars: medical devices, health data, and therapeutic drugs. I am joining a globally recognized and experienced team who has been tasked with transforming the collection of procedural and patient data using a new global platform that leverages smart wireless medical technologies. This platform seeks to provide new techniques for both therapeutic drug discovery and the improvement of medical procedures, all of which translates to better outcomes for patients. My combined experiences to date have provided me with the unique skills to lead this multi-disciplinary team of technologists, scientists, and engineers.”

“Xenter is continuing our commitment to bringing the most experienced and visionary leaders to the world’s first purpose-built medical device-data-drug company and tasking them with introducing change, developing new wireless platforms for smart medical devices, and harnessing the power of Physical Intelligence to improve patient care. As a former patient, my goal has been to work with people like Mark Turco, MD, to develop the medical technologies platform of the future and characterize the differences between AI and PI,” stated Richard J. Linder, Founder, Chairman and CEO of Xenter, Inc. “Dr. Turco brings a wealth of skill and insight to Xenter and possesses the clinical knowledge and industry experience to drive the change we desire to achieve in medical devices and data.”

“We believe that medical data should be owned by patients, that ease of accessibility to medical data is of vital importance to both physicians and patients, and that new global platforms are needed for the collection and management of medical data,” continued Mr. Linder. “I’m looking forward to working with Dr. Turco as we relentlessly pursue the development of Xenter’s new wireless platform.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy